MetaTrader
  • Mercati
  • Grafici & Idee
  • Algo
  • Notizie
  • Store
  • Broker
  • Scarica
  • Calendario Economico
  • Segnali di Trading
  • Terminale Web
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
Cardiol Therapeutics Inc. Class A Common Shares

CRDL

#5403
Cardiol Therapeutics Inc. Class A Common Shares
1.02
-0.97%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
1.02
1.02
Intervallo Annuale
0.77
1.59
Variazione giornaliera
-0.97%
Variazione Mensile
+4.08%
Variazione di 6 mesi
-8.93%
Variazione Annuale
-13.56%
Chiusura Precedente
1.03
Open
1.02
Bid
Ask
Low
1.02
High
1.02
Volume
3
  1. Mercati
  2. Mercato Azionario Statunitense
  3. Salute
  4. CRDL
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Value 202220232024 TTM

Notizie

Investing Investing
CRDL
2026.02.10
Cardiol Therapeutics veröffentlicht positive Phase-II-Studienergebnisse zu Myokarditis
Investing Investing
CRDL
2026.02.10
Cardiol Therapeutics publishes phase II myocarditis study results
Investing Investing
CRDL
2026.02.02
Cardiol Therapeutics legt Emissions­garantie­vertrag und Options­schein­vereinbarung vor/n
Investing Investing
CRDL
2026.02.02
Cardiol Therapeutics files underwriting agreement and warrant indenture
Investing Investing
CRDL
2026.01.16
Cardiol Therapeutics sichert sich 13,5 Millionen US-Dollar durch Privatplatzierung
Investing Investing
CRDL
2026.01.16
Cardiol Therapeutics announces $13.5 million private placement
Investing Investing
CRDL
2026.01.16
Cardiol Therapeutics sichert sich 13,5 Millionen US-Dollar durch Bought-Deal-Finanzierung
Investing Investing
CRDL
2026.01.16
Cardiol Therapeutics announces $13.5 million bought deal financing
Investing Investing
CRDL
2026.01.13
Cardiol Therapeutics: Hälfte der Patienten für Phase-III-Studie zu rezidivierender Perikarditis rekrutiert
Investing Investing
CRDL
2026.01.13
Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial
Investing Investing
CRDL
2025.12.02
H.C. Wainwright bestätigt Kaufempfehlung für Cardiol Therapeutics mit Kursziel von 9 $
Investing Investing
CRDL
2025.12.02
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target

Mercati

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Grafici & Idee

  • Idee di Trading
  • Idee Educative
  • Grafici

MQL5 Community

  • Market
  • Segnali
  • Forum
  • Articoli
  • CodeBase

Notizie

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Broker

  • Tutti i Broker
  • Forex
  • Azioni
  • Metalli
MetaTrader 5
MQL5 Channels
Economic Calendar
Esclusione di Responsabilità e Informativa sui Rischi Termini di Utilizzo Contatti e richieste Legale
Copyright 2000-2026, MetaQuotes Ltd